Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials
YeXing Huang(Sun Yat-sen University), Anna Kan(Sun Yat-sen University), ZhiCheng Lai(Sun Yat-sen University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Zhongguo Zhou(Sun Yat-sen University), Dongsheng Wen(Technical University of Munich), Ming Shi(Yanshan University), YaoJun Zhang(Sun Yat-sen University), MinShan Chen(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Lihong Zhang(Anhui Agricultural University), Xiaoyun Bu(Xiamen Blood Center), QiJiong Li(Sun Yat-sen University), Minke He(Sun Yat-sen University), Rong Guo(Sun Yat-sen University)
Cited by 8
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216